These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33972830)

  • 1. CRP is a superior and prognostically significant inflammation biomarker for hepatocellular cancer patients treated by liver transplantation.
    Carr BI; Ince V; Bag HG; Usta S; Ersan V; Isik B; Yilmaz S
    Clin Pract (Lond); 2021; 18(2):1626-1632. PubMed ID: 33972830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood platelet counts identify prognostically diverse clinical phenotypes in hepatocellular carcinoma.
    Carr BI; Bag HG; Yilmaz S
    Ann Gastroenterol Dig Syst; 2024; 7(1):. PubMed ID: 38887309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory markers C-reactive protein and PLR in relation to HCC characteristics.
    Suner A; Carr BI; Akkiz H; Uskudar O; Kuran S; Tokat Y; Tokmak S; Ballı T; Ulku A; AkCam T; Delik A; Arslan B; Doran F; YalCın K; Ekinci N; Yilmaz S; Ozakyol A; Yücesoy M; BahCeci HI; Polat KY; Şimsek H; Ormeci N; Sonsuz A; Demir M; KılıC M; Uygun A; Demir A; Altıntas E; Karakulah G; Temel T; Bektas A
    J Transl Sci; 2019 Jun; 5(3):. PubMed ID: 30662766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma.
    Carr BI; Guerra V; Donghia R
    J Gastrointest Cancer; 2020 Dec; 51(4):1141-1147. PubMed ID: 32851544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-Reactive Protein and Platelet-Lymphocyte Ratio as Potential Tumor Markers in Low-Alpha-Fetoprotein Hepatocellular Carcinoma.
    Suner A; Carr BI; Akkiz H; Karakülah G; Üsküdar O; Yalçın K; Kuran S; Tokat Y; Yilmaz S; Özakyol A; Tokmak S; Ballı T; Yücesoy M; Bahçeci Hİ; Ülkü A; Akçam T; Polat KY; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Demir A; Delik A; Arslan B; Doran F; Altıntaş E; Temel T; Bektaş A
    Oncology; 2019; 96(1):25-32. PubMed ID: 30336489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of gamma-glutamyl transpeptidase in relation to HCC human biology and prognosis.
    Carr BI; Akkiz H; Bag HG; Karaoğullarından U; Yalçın K; Ekin N; Özakyol A; Altıntaş E; Balaban HY; Şimşek H; Uyanıkoğlu A; Balkan A; Kuran S; Üsküdar O; Ülger Y; Güney B; Delik A
    J Transl Sci; 2021 Jun; 7(3):. PubMed ID: 34540270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation.
    Ince V; Carr BI; Bag HG; Koc C; Usta S; Ersan V; Baskiran A; Sahin TT; Yilmaz S
    Int J Biol Markers; 2020 Jun; 35(2):91-95. PubMed ID: 32436751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordance among aggressiveness characteristics of hepatocellular carcinoma: Portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein level.
    Carr BI; Guerra V; Ince V; Isik B; Yilmaz S
    Liver Res; 2023 Sep; 7(3):256-262. PubMed ID: 37854945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Tumor Indices in Relation to Increased Hepatocellular Carcinoma Size: Evidence for Tumor Evolution as a Function of Growth.
    Carr BI; Guerra V; Donghia R; Yilmaz S
    J Gastrointest Cancer; 2020 Dec; 51(4):1215-1219. PubMed ID: 33006073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of inflammatory markers CRP, ESR and albumin in relation to survival for patients with hepatocellular carcinoma.
    Akkiz H; Carr BI; Bag HG; Karaoğullarından Ü; Yalçın K; Ekin N; Özakyol A; Altıntaş E; Balaban HY; Şimşek H; Uyanıkoğlu A; Balkan A; Kuran S; Üsküdar O; Ülger Y; Güney B; Delik A
    Int J Clin Pract; 2021 Feb; 75(2):e13593. PubMed ID: 32583494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors.
    Carr BI; Akkiz H; Guerra V; Üsküdar O; Kuran S; Karaoğullarından Ü; Tokmak S; Ballı T; Ülkü A; Akçam T; Delik A; Arslan B; Doran F; Yalçın K; Altntaş E; Özakyol A; Yücesoy M; Bahçeci Hİ; Polat KY; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Demir A; Yilmaz S; Tokat Y
    Clin Pract (Lond); 2018; 15(Spec Issue):625-634. PubMed ID: 29951199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplant and non-transplant HCC patients at a single institution.
    Carr BI; Bag H; Ince V; Isik B; Baskiran A; Yilmaz S
    Hepatol Forum; 2024; 5(2):77-86. PubMed ID: 38487742
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Abouchaleh N; Gabr A; Ali R; Al Asadi A; Mora RA; Kallini JR; Mouli S; Riaz A; Lewandowski RJ; Salem R
    J Nucl Med; 2018 Jul; 59(7):1042-1048. PubMed ID: 29217739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios predict tumor size and survival in HCC patients: Retrospective study.
    Suner A; Carr BI
    Ann Med Surg (Lond); 2020 Oct; 58():167-171. PubMed ID: 32994979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCs.
    Carr BI; Guerra V; Donghia R; Farinati F; Giannini EG; Muratori L; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Sacco R; Celsa C; Campani C; Mega A; Guarino M; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Biasini E; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Brunetto MR; Trevisani F
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33546234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes.
    Carr BI; Guerra V; Donghia R; Yilmaz S
    Ann Med Surg (Lond); 2021 Jun; 66():102458. PubMed ID: 34141428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macroscopic Portal Vein Thrombosis in HCC Patients.
    Akkiz H; Carr BI; Kuran S; Karaoğullarından Ü; Üsküdar O; Tokmak S; Arslan B; Doran F; Balli HT; Ülkü A; Akçam TA; Bahçeci Hİ; Polat KY; Örmeci N; Şimşek H; Sonsuz A; Demir A; Altıntaş E; Demir M; Yalçın K; Ekinci N; Harmancı Özakyol A; Yücesoy M; Uygun A; Guerra V; Delik A; Tokat Y; Yilmaz S; Bektaş A; Kılıç M
    Can J Gastroenterol Hepatol; 2018; 2018():3120185. PubMed ID: 30009156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCC with low- and normal-serum alpha-fetoprotein levels.
    Carr BI; Akkiz H; Üsküdar O; Yalçın K; Guerra V; Kuran S; Karaoğullarından Ü; Altıntaş E; Özakyol A; Tokmak S; Ballı T; Yücesoy M; Bahçeci Hİ; Ülkü A; Akçam T; Polat KY; Ekinci N; Şimşek H; Örmeci N; Sonsuz A; Demir M; Kılıç M; Uygun A; Demir A; Delik A; Arslan B; Doran F; Yilmaz S; Tokat Y
    Clin Pract (Lond); 2018; 15(1):453-464. PubMed ID: 29576865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low alpha-fetoprotein HCC and the role of GGTP.
    Carr BI; Guerra V; Giannini EG; Farinati F; Ciccarese F; Rapaccini GL; Di Marco M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F
    Int J Biol Markers; 2014 Dec; 29(4):e395-402. PubMed ID: 24832180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplant for large hepatocellular carcinoma in Malatya: The role of gamma glutamyl transferase and alpha-fetoprotein, a retrospective cohort study.
    Ince V; Carr BI; Bag HG; Ersan V; Usta S; Koc C; Gonultas F; Sarici BK; Karakas S; Kutluturk K; Baskiran A; Yilmaz S
    World J Gastrointest Surg; 2020 Dec; 12(12):520-533. PubMed ID: 33437403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.